Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5219_Библиотеки_им_академика_М_И_Перельмана.pdf
14 Therapeutic Strategies and Challenges in the Management of Aspergillus…
The development of echinocandin resistance involves mutations in the FKS1
gene, resulting in a conformational change in the encoded enzyme and a subsequent
reduction in the afnity between Fks1 and echinocandins (Gonçalves etal. 2016).
In A. fumigatus mutant with an amino acid, substitution S678P in Fks1p has been
reported which results in its resistance to echinocandins (Rocha etal. 2007).
Flucytosine, or 5-uorocytosine, is a synthetic antimycotic compound that is
typically employed in combination with amphotericin B to treat severe fungal infections, particularly those instigated by Candida species and Cryptococcus. The drug
operates by being converted within susceptible fungal cells into the active metabolite, 5-uorouracil (5-FU), and subsequent intermediate metabolites. These metabolites disrupt fungal DNA, RNA, and protein synthesis, culminating in the death of
the fungal cell (Chandra and Ghannoum 2017).
Resistance to ucytosine can develop rapidly during monotherapy, thereby limit-
ing its use (Rogers etal. 2022). This resistance is predominantly associated with
mutations affecting key areas, including mutations in the FUR1 gene and cellular
drug uptake. FUR1 gene encodes uracil phosphoribosyl transferase (UPRT), an
enzyme implicated in the conversion of ucytosine to 5-FU.Mutations in FUR1 can
diminish or eliminate the activity of UPRT, rendering the conversion of ucytosine
less effective and leading to resistance (Vandeputte etal. 2011). Resistance can also
arise through mutations that affect the cellular uptake of ucytosine. This prevents
the drug from entering susceptible fungal cells and being converted into its active
form. Understanding these mechanisms of resistance is critical for devising effective antifungal treatment strategies and continuing the ght against fungal infections.
353
14.7 Aspergillus Co-Infections: Impact, Challenges,
andManagement
Coinfection is dened as the simultaneous presence of two or more infections, a
condition that has the potential to extend both the length and severity of each infection (Stedman 2012).
14.7.1 Co-Infections inPulmonary TB
Aspergillus spp. can invade a patient’s lungs already been infected with
Mycobacterium tuberculosis, thus causing additional health issues and complica-
tions (Santos etal. 2014). Even after completing the entire course of TB treatment,
patients continue to suffer from persistent pulmonary complications due to secondary infections caused by fungi, such as Aspergillus. This phenomenon draws attention to the proper analysis of all fungi found in clinical samples, particularly in
immunocompromised patients (Mathavi etal. 2014). The complication arises from
the similarity in symptoms for both TB and pulmonary fungal co-infection. To
address this issue, if direct smear and culture tests for TB come back negative, it is
354
D. Das et al.
advisable to further examine specimens for the presence of Aspergillus or any other
infectious fungi (Hosseini etal. 2020).
14.7.2 Co-Infections inCOVID-19 Patients
COVID-19-associated pulmonary aspergillosis (CAPA) is intricately linked with
prolonged hospitalization and an array of predisposing risk factors (van de Veerdonk
etal. 2021). These risk factors encompass various fungal elements, including nosocomial strains, conidia size, and the respiratory tract colonization potential of
Aspergillus spp. Environmental considerations such as hospital structural modications, the use of air conditioning systems, and the implementation of negative pressure environments within intensive care units also play a signicant role.
Comorbidities and immunosuppressive therapies further contribute to this complex
landscape. Notably, SARS-CoV-2 itself induces substantial dysfunction in the
patient’s immune system, affecting both innate and adaptive immunity, leading to
diminished CD4+ and CD8+ T-cell counts and the emergence of a cytokine storm
(Castro-Fuentes etal. 2022).
Among the primary host risk factors associated with CAPA are the severity of
COVID-19, advanced age, pre-existing respiratory conditions, chronic renal failure,
neutropenia, and extended treatment with corticosteroids or tocilizumab for
COVID-19 management. In addition, factors such as thrombocytopenia, the use of
vasopressors before CAPA diagnosis, azithromycin treatment, and methylprednisolone administration also merit consideration, as they are relevant comorbidities in
the context of CAPA development (Castro-Fuentes etal. 2022).
Voriconazole has seen extensive utilization in the management of
CAPA.Nevertheless, apprehensions have arisen due to potential drug interactions
between voriconazole and medications employed in COVID-19 treatment, such as
hydroxychloroquine, azithromycin, and protease inhibitors, such as lopinavir/ritonavir, which have been linked to cardiac events. As a result, these drug interactions
have compromised the efcacy of voriconazole as a treatment option for CAPA
patients, underscoring its limited effectiveness, a concern that has also been observed
with itraconazole (Giudicessi et al. 2020; Jenks et al. 2019; Santos et al. 2014;
Varshneya etal. 2021).
14.7.3 Co-Infections inOrgan Transplant Recipients
In solid-organ transfer (SOT) recipients, though IA is uncommon, but it is extremely
severe (Neofytos etal. 2018; Pappas etal. 2010). High rates of graft loss and mortality are the additional cons associated with it (Farmakiotis and Kontoyiannis 2015).
Less than 10% of SOT recipients suffer from IA, the incidence varies based on the
type of transplanted organs (Neofytos etal. 2018; Singh and Husain 2013). The
rates of mortality within 3months can be particularly high, reaching 15–25% for
non-liver transplant recipients and 80–90% for liver transplant recipients (Neofytos
14 Therapeutic Strategies and Challenges in the Management of Aspergillus…
355
etal. 2018). This complication and serious clinical issue are being addressed by
administering antifungal drugs by transplant centers, but the use of such broadspectrum drugs is a topic of controversy (Lamoth etal. 2017; Neoh et al. 2011).
There were several attempts to personalize this antifungal therapy based on the
clinical symptoms and IA risk factors, but it failed to see the light of success
(Winston etal. 2014).
14.8 Conclusion
This chapter provides valuable insights into various aspects of Aspergillus-related
infections and their treatment strategies. These infections pose a signicant health
challenge, especially in immunocompromised individuals and thus, demand
improved and more effective treatment options. These therapeutic strategies encompass a wide range of approaches, ranging from well-established antifungal agents,
preventive vaccines, and monoclonal antibodies to cutting-edge nanotechnologybased therapies. Concurrently, research efforts are delving into immune therapy and
combination therapy, with emerging ndings on the potential of cytokines and
immunostimulants such as IFNγ and TNF-α to strengthen the immune system
against aspergillosis. Recent developments, such as DC therapy, NK cell therapy,
and CAR-T-cell therapy, contribute as the latest additions to the evolving eld of
Aspergillus treatment.
A signicant challenge in treating Aspergillus infections is when it co-exists in
various clinical manifestations, such as pulmonary TB, COVID-19, and organ transplant recipients. Future research directions should emphasize on the development of
novel antifungal agents, biomarkers, and immunotherapies, with a crucial focus on
optimizing recently developed therapies. A multidisciplinary and collaborative
approach is thus essential to advance the knowledge and prevention strategies for
aspergillosis in clinical settings, which can help to improve patient outcomes.
Conict of Interest The authors declare no conict of interest.
References
Abers MS, Ghebremichael MS, Timmons AK, Warren HS, Poznansky MC, Vyas JM (2016) A
critical reappraisal of prolonged neutropenia as a risk factor for invasive pulmonary aspergillosis. Open Forum Infect Dis 3(1):ofw036. https://doi.org/10.1093/od/ofw036
Agarwal R, Aggarwal AN, Gupta D, Jindal SK (2009) Aspergillus hypersensitivity and allergic
bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and
meta-analysis. Int J Tuberc Lung Dis 13(8):936–944
Arndt S, Aschendorff A, Echternach M, Daemmrich TD, Maier W (2009) Rhino-orbital-
cerebral mucormycosis and aspergillosis: differential diagnosis and treatment. Eur Arch
Otorhinolaryngol 266(1):71–76. https://doi.org/10.1007/s00405- 008- 0692- y
Bacher P, Jochheim-Richter A, Mockel-Tenbrink N, Kniemeyer O, Wingenfeld E, Alex R,
Ortigao A, Karpova D, Lehrnbecher T, Ullmann AJ, Hamprecht A, Cornely O, Brakhage
AA, Assenmacher M, Bonig H, Scheffold A (2015) Clinical-scale isolation of the total
356
aspergillus fumigatus–reactive T–helper cell repertoire for adoptive transfer. Cytotherapy
17(10):1396–1405. https://doi.org/10.1016/j.jcyt.2015.05.011
Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, Oster RA,
Anaissie EJ, Walsh TJ, Schuster MG, Wingard JR, Patterson TF, Ito JI, Williams OD, Chiller T,
Pappas PG (2010) Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 50(12):1559–1567. https://doi.org/10.1086/652768
Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature
392(6673):245–252. https://doi.org/10.1038/32588
Bartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L, Fornaro G, Tonetti T, Pizzilli
G, Francalanci E, Giuntoli L, Rubin A, Moroni A, Ambretti S, Trapani F, Vatamanu O, Ranieri
VM, Castelli A, Baiocchi M etal (2021) Epidemiology of invasive pulmonary aspergillosis
among intubated patients with COVID-19: a prospective study. Clin Infect Dis 73(11):e3606–
e3614. https://doi.org/10.1093/cid/ciaa1065
Bassetti M, Bouza E (2017) Invasive mould infections in the ICU setting: complexities and solu-
tions. J Antimicrob Chemother 72(suppl_1):i39–i47. https://doi.org/10.1093/jac/dkx032
Baygar T, Sarac N, Ugur A, Karaca IR (2019) Antimicrobial characteristics and biocompatibility of
the surgical sutures coated with biosynthesized silver nanoparticles. Bioorg Chem 86:254–258.
https://doi.org/10.1016/j.bioorg.2018.12.034
Berman J, Krysan DJ (2020) Drug resistance and tolerance in fungi. Nat Rev Microbiol
18(6):319–331. https://doi.org/10.1038/s41579- 019- 0322- 2
Blatzer M, Blum G, Jukic E, Posch W, Gruber P, Nagl M, Binder U, Maurer E, Sarg B, Lindner
H, Lass-Flörl C, Wilingseder D (2015) Blocking Hsp70 enhances the efciency of amphotericin B treatment against resistant Aspergillus terreus strains. Antimicrob Agents Chemother
59(7):3778–3788. https://doi.org/10.1128/AAC.05164- 14
Blum G, Kainzner B, Grif K, Dietrich H, Zeiger B, Sonnweber T, Lass-Flörl C (2013) In vitro and
invivo role of heat shock protein 90in amphotericin B resistance of Aspergillus terreus. Clin
Microbiol Infect 19(1):50–55. https://doi.org/10.1111/j.1469- 0691.2012.03848.x
Bowden R, Chandrasekar P, White MH, Li X, Pietrelli L, Gurwith M, van Burik J, Laverdiere M,
Safrin S, Wingard JR (2002) A double-blind, randomized, controlled trial of amphotericin B
colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35(4):359–366. https://doi.org/10.1086/341401
Bozza S, Gaziano R, Lipford GB, Montagnoli C, Bacci A, Di Francesco P, Kurup VP, Wagner H,
Romani L (2002) Vaccination of mice against invasive aspergillosis with recombinant aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 4(13):1281–1290.
https://doi.org/10.1016/S1286- 4579(02)00007- 2
Bozza S, Perruccio K, Montagnoli C, Gaziano R, Bellocchio S, Burchielli E, Nkwanyuo G,
Pitzurra L, Velardi A, Romani L (2003) A dendritic cell vaccine against invasive aspergillosis in
allogeneic hematopoietic transplantation. Blood 102(10):3807–3814. https://doi.org/10.1182/
blood- 2003- 03- 0748
Bozza S, Clavaud C, Giovannini G, Fontaine T, Beauvais A, Sarfati J, D’Angelo C, Perruccio K,
Bonifazi P, Zagarella S, Moretti S, Bistoni F, Latgé J-P, Romani L (2009) Immune sensing of
Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunol 183(4):2407–2414. https://doi.org/10.4049/jimmunol.0900961
Briard B, Fontaine T, Kanneganti T-D, Gow NAR, Papon N (2021) Fungal cell wall components
modulate our immune system. Cell Surf 7:100067. https://doi.org/10.1016/j.tcsw.2021.100067
Buil JB, Meis JF, Melchers WJG, Verweij PE (2016) Are the TR 46 /Y121F/T289A mutations in
azole-resistant aspergillosis patient acquired or environmental? Antimicrob Agents Chemother
60(5):3259–3260. https://doi.org/10.1128/AAC.00256- 16
Calero AL, Alonso R, Gadea I, Vega MDM, García MM, Muñoz P, Machado M, Bouza E, García-
Rodríguez J (2022) Comparison of the performance of two galactomannan detection tests:
Platelia Aspergillus Ag and Aspergillus galactomannan Ag Virclia Monotest. Microbiol Spectr
10(2):e0262621. https://doi.org/10.1128/spectrum.02626- 21
Candoni A, Klimko N, Busca A, Di Blasi R, Shadrivova O, Cesaro S, Zannier ME, Verga L,
Forghieri F, Calore E, Nadali G, Simonetti E, Muggeo P, Quinto AM, Castagnola C, Cellini M,
D. Das et al.
14 Therapeutic Strategies and Challenges in the Management of Aspergillus…
Del Principe MI, Fracchiolla N, Melillo L etal (2019) Fungal infections of the central nervous
system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting
the diagnostic-therapeutic approach and outcome in 89 cases. Mycoses 62(3):252–260. https://
doi.org/10.1111/myc.12884
Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M,
Goffeau A, Monk BC (2009) Efux-mediated antifungal drug resistance. Clin Microbiol Rev
22(2):291–321. https://doi.org/10.1128/CMR.00051- 08
Carmona EM, Limper AH (2017) Overview of treatment approaches for fungal infections. Clin
Chest Med 38(3):393–402. https://doi.org/10.1016/j.ccm.2017.04.003
Castellano-Gonzalez G, Clancy LE, Gottlieb D (2017) Prospects for adoptive T-cell therapy
for invasive fungal disease. Curr Opin Infect Dis 30(6):518–527. https://doi.org/10.1097/
QCO.0000000000000403
Castro-Fuentes CA, del Reyes-Montes M, Frías-De-León MG, Valencia-Ledezma OE, Acosta-
Altamirano G, Duarte-Escalante E (2022) Aspergillus-SARS-CoV-2 coinfection: what is
known? Pathogens 11(11):1227. https://doi.org/10.3390/pathogens11111227
Cenci E, Mencacci A, Del Sero G, Bacci A, Montagnoli C, d’Ostiani CF, Mosci P, Bachmann M,
Bistoni F, Kopf M, Romani L (1999) Interleukin-4 causes susceptibility to invasive pulmonary
aspergillosis through suppression of protective type I responses. J Infect Dis 180(6):1957–1968.
https://doi.org/10.1086/315142
Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L (2000) T cell vaccination in mice
with invasive pulmonary aspergillosis. J Immunol 165(1):381–388. https://doi.org/10.4049/
jimmunol.165.1.381
Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis
DP (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary
care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica
91(7):986–989
Chandra J, Ghannoum MA (2017) Flucytosine treatment and resistance mechanisms. In:
Antimicrobial drug resistance. Springer International, Berlin, pp 407–413. https://doi.
org/10.1007/978- 3- 319- 46718- 4_28
Chotirmall SH, Al-Alawi M, Mirkovic B, Lavelle G, Logan PM, Greene CM, McElvaney NG
(2013) Aspergillus-associated airway disease, inammation, and the innate immune response.
Biomed Res Int 2013:1–14. https://doi.org/10.1155/2013/723129
Comez AT, Komur B, Akcali A, Otkun MT (2012) Ocular aspergillosis: obtaining a specimen is
crucial for diagnosis. A report of three cases. Med Mycol Case Rep 1(1):39–41. https://doi.
org/10.1016/j.mmcr.2012.06.002
DeLone DR, Goldstein RA, Petermann G, Salamat MS, Miles JM, Knechtle SJ, Brown WD (1999)
Disseminated aspergillosis involving the brain: distribution and imaging characteristics. AJNR
Am J Neuroradiol 20(9):1597–1604
Denning DW (1998) Invasive Aspergillosis. Clin Infect Dis 26(4):781–803. https://doi.
org/10.1086/513943
Dreizen S, Bodey GP, McCredie KB, Keating MJ (1985) Orofacial aspergillosis in acute leukemia.
Oral Surg Oral Med Oral Pathol 59(5):499–504. https://doi.org/10.1016/0030- 4220(85)90091- X
Economides MP, Ballester LY, Kumar VA, Jiang Y, Tarrand J, Prieto V, Torres HA, Kontoyiannis
DP (2017) Invasive mold infections of the central nervous system in patients with hematologic
cancer or stem cell transplantation (2000–2016): uncommon, with improved survival but still
deadly often. J Infect 75(6):572–580. https://doi.org/10.1016/j.jinf.2017.09.011
Farmakiotis D, Kontoyiannis DP (2015) Emerging issues with diagnosis and management of fun-
gal infections in solid organ transplant recipients. Am J Transplant 15(5):1141–1147. https://
doi.org/10.1111/ajt.13186
Fernandes CM, Normile TG, Fabri JHTM, Brauer VS, de Araújo GR, Frases S, Nimrichter L,
Malavazi I, Del Poeta M (2022) Vaccination with live or heat-killed aspergillus fumigatus
Δ sglA conidia fully protects immunocompromised mice from invasive aspergillosis. MBio
13(5):e0232822. https://doi.org/10.1128/mbio.02328- 22
357
358
Findlay GH, Roux HF, Simson IW (1971) Skin manifestations of disseminated aspergillosis. Br J
Dermatol 85:94
Fisher BT, Westling T, Boge CLK, Zaoutis TE, Dvorak CC, Nieder M, Zerr DM, Wingard JR,
Villaluna D, Esbenshade AJ, Alexander S, Gunn S, Wheat LJ, Sung L (2021) Prospective evaluation of galactomannan and (1→3) β--glucan assays as diagnostic tools for invasive fungal
disease in children, adolescents, and Young adults with acute myeloid leukemia receiving fungal prophylaxis. J Pediatr Infect Dis Soc 10(8):864–871. https://doi.org/10.1093/jpids/piab036
Gamaletsou MN, Rammaert B, Bueno MA, Moriyama B, Sipsas NV, Kontoyiannis DP, Roilides
E, Zeller V, Prinapori R, Taj-Aldeen SJ, Brause B, Lortholary O, Walsh TJ (2014) Aspergillus
osteomyelitis: epidemiology, clinical manifestations, management, and outcome. J Infect
68(5):478–493. https://doi.org/10.1016/j.jinf.2013.12.008
Gefter WB, Weingrad TR, Epstein DM, Ochs RH, Miller WT (1981) “Semi-invasive” pulmo-
nary aspergillosis: a new look at the spectrum of aspergillus infections of the lung. Radiology
140(2):313–321. https://doi.org/10.1148/radiology.140.2.7255704
Ghanaie R, Karimi A, Fahimzad A, Armin S, Shiva F (2015) Fungal dacryocystitis. J Pediatr Infect
Dis 05(03):293–296. https://doi.org/10.3233/JPI- 2010- 0247
Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ (2020) Urgent guidance for navigat-
ing and circumventing the QTc-prolonging and Torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc 95(6):1213–1221. https://
doi.org/10.1016/j.mayocp.2020.03.024
Gonçalves SS, Souza ACR, Chowdhary A, Meis JF, Colombo AL (2016) Epidemiology and molec-
ular mechanisms of antifungal resistance in Candida and Aspergillus. Mycoses 59(4):198–219.
https://doi.org/10.1111/myc.12469
Gonzales Zamora J, Henry Z, Gultekin S (2018) Central nervous system aspergillosis: an unex-
pected complication following neurosurgery. Diseases 6(2):46. https://doi.org/10.3390/
diseases6020046
Guarner J, Brandt ME (2011) Histopathologic diagnosis of fungal infections in the 21st century.
Clin Microbiol Rev 24(2):247–280. https://doi.org/10.1128/CMR.00053- 10
Hansen D, Blahout B, Benner D, Popp W (2008) Environmental sampling of particulate matter and
fungal spores during demolition of a building on a hospital area. J Hosp Infect 70(3):259–264.
https://doi.org/10.1016/j.jhin.2008.07.010
Hebart H, Bollinger C, Fisch P, Sarfati J, Meisner C, Baur M, Loefer J, Monod M, Latgé J-P,
Einsele H (2002) Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy
individuals and patients with hematologic malignancies. Blood 100(13):4521–4528. https://
doi.org/10.1182/blood- 2002- 01- 0265
Hope WW, Walsh TJ, Denning DW (2005) The invasive and saprophytic syndromes due to
Aspergillus spp. Med Mycol 43(s1):207–238. https://doi.org/10.1080/13693780400025179
Hosseini M, Shakerimoghaddam A, Ghazalibina M, Khaledi A (2020) Aspergillus coinfec-
tion among patients with pulmonary tuberculosis in Asia and Africa countries; a systematic
review and meta-analysis of cross-sectional studies. Microb Pathog 141:104018. https://doi.
org/10.1016/j.micpath.2020.104018
Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M,
Arendrup MC, Perlin DS, Denning DW (2009) Frequency and evolution of azole resistance in
Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15(7):1068–1076.
https://doi.org/10.3201/eid1507.090043
Hussain A, Singh VK, Singh OP, Shafaat K, Kumar S, Ahmad FJ (2016) Formulation and optimi-
zation of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of
amphotericin B.Drug Deliv 23(8):3101–3110. https://doi.org/10.3109/10717544.2016.115374
7
Ito JI, Lyons JM, Hong TB, Tamae D, Liu Y-K, Wilczynski SP, Kalkum M (2006) Vaccinations
with recombinant variants of Aspergillus fumigatus allergen asp f 3 protect mice against invasive aspergillosis. Infect Immun 74(9):5075–5084. https://doi.org/10.1128/IAI.00815- 06
D. Das et al.
14 Therapeutic Strategies and Challenges in the Management of Aspergillus…
Jenks JD, Mehta SR, Hoenigl M (2019) Broad spectrum triazoles for invasive mould infections
in adults: which drug and when? Med Mycol 57(Supplement_2):S168–S178. https://doi.
org/10.1093/mmy/myy052
Jensen J, Guinea J, Torres-Narbona M, Muñoz P, Peláez T, Bouza E (2010) Post-surgical invasive
aspergillosis: an uncommon and under-appreciated entity. J Infect 60(2):162–167. https://doi.
org/10.1016/j.jinf.2009.11.005
Jesmin R, Chanda A (2020) Restricting mycotoxins without killing the producers: a new para-
digm in nano-fungal interactions. Appl Microbiol Biotechnol 104(7):2803–2813. https://doi.
org/10.1007/s00253- 020- 10373- w
Jolink H, Hagedoorn RS, Lagendijk EL, Drijfhout JW, van Dissel JT, Falkenburg JHF, Heemskerk
MHM (2014) Induction of A.Fumigatus-specic CD4-positive T cells in patients recovering from invasive aspergillosis. Haematologica 99(7):1255–1263. https://doi.org/10.3324/
haematol.2013.098830
Kakoschke TK, Kleinemeier C, Knösel T, Kakoschke SC, Ebel F (2023) The novel monoclo-
nal IgG1-antibody AB90-E8 as a diagnostic tool to rapidly distinguish Aspergillus fumigatus
from other human pathogenic aspergillus species. J Fungi 9(6):622. https://doi.org/10.3390/
jof9060622
Kanj A, Abdallah N, Soubani AO (2018) The spectrum of pulmonary aspergillosis. Respir Med
141:121–131. https://doi.org/10.1016/j.rmed.2018.06.029
Khalil NM, Abd El-Ghany MN, Rodríguez-Couto S (2019) Antifungal and anti-mycotoxin ef-
cacy of biogenic silver nanoparticles produced by fusarium chlamydosporum and Penicillium
chrysogenum at non-cytotoxic doses. Chemosphere 218:477–486. https://doi.org/10.1016/j.
chemosphere.2018.11.129
Khoo SH, Denning DW (1994) Invasive aspergillosis in patients with AIDS. Clin Infect Dis
19(Supplement_1):S41–S48. https://doi.org/10.1093/clinids/19.Supplement_1.S41
Koo S, Thomas HR, Daniels SD, Lynch RC, Fortier SM, Shea MM, Rearden P, Comolli JC, Baden
LR, Marty FM (2014) A breath fungal secondary metabolite signature to diagnose invasive
aspergillosis. Clin Infect Dis 59(12):1733–1740. https://doi.org/10.1093/cid/ciu725
Kosinska AD, Bauer T, Protzer U (2017) Therapeutic vaccination for chronic hepatitis B.Curr
Opin Virol 23:75–81. https://doi.org/10.1016/j.coviro.2017.03.011
Kousha M, Tadi R, Soubani AO (2011) Pulmonary aspergillosis: a clinical review. Eur Respir Rev
20(121):156–174. https://doi.org/10.1183/09059180.00001011
Kristinsson JK, Sigurdsson H (1998) Lacrimal sac plugging caused by Aspergillus fumigatus. Acta
Ophthalmol Scand 76(2):241–242. https://doi.org/10.1034/j.1600- 0420.1998.760224.x
Kumar M, Mugunthan M (2019) β-D-glucan and aspergillus galactomannan assays in the diag-
nosis of invasive fungal infections. Med J Armed Forces India 75(4):357–360. https://doi.
org/10.1016/j.mja.2017.10.005
Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares
S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, Kontoyiannis DP,
Cooper LJN (2014) Bioengineering T cells to target carbohydrate to treat opportunistic fungal
infection. Proc Natl Acad Sci 111(29):10660–10665. https://doi.org/10.1073/pnas.1312789111
Lamoth F, Chung SJ, Damonti L, Alexander BD (2017) Changing epidemiology of invasive mold
infections in patients receiving azole prophylaxis. Clin Infect Dis 64(11):1619–1621. https://
doi.org/10.1093/cid/cix130
Latgé JP (1999) Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12(2):310–350.
https://doi.org/10.1128/CMR.12.2.310
Lehrnbecher T, Kalkum M, Champer J, Tramsen L, Schmidt S, Klingebiel T (2013)
Immunotherapy in invasive fungal infection—focus on invasive aspergillosis. Curr Pharm Des
19(20):3689–3712. https://doi.org/10.2174/1381612811319200010
Levitz SM, Golenbock DT (2012) Beyond empiricism: informing vaccine development through
innate immunity research. Cell 148(6):1284–1292. https://doi.org/10.1016/j.cell.2012.02.012
359
360
Lian X, Scott-Thomas A, Lewis JG, Bhatia M, Chambers ST (2022a) A novel monoclonal anti-
body 1D2 that broadly inhibits clinically important aspergillus species. J Fungi 8(9):960.
https://doi.org/10.3390/jof8090960
Lian X, Scott-Thomas A, Lewis JG, Bhatia M, MacPherson SA, Zeng Y, Chambers ST (2022b)
Monoclonal antibodies and invasive aspergillosis: diagnostic and therapeutic perspectives. Int
J Mol Sci 23(10):5563. https://doi.org/10.3390/ijms23105563
Libshitz HI, Pagani JJ (1981) Aspergillosis and mucormycosis: two types of opportunistic fungal
pneumonia. Radiology 140(2):301–306. https://doi.org/10.1148/radiology.140.2.7019958
Livengood SJ, Drew RH, Perfect JR (2020) Combination therapy for invasive fungal infections.
Curr Fungal Infect Rep 14(1):40–49. https://doi.org/10.1007/s12281- 020- 00369- 4
Marr KA, Boeckh M, Carter RA, Kim HW, Corey L (2004) Combination antifungal therapy for
invasive aspergillosis. Clin Infect Dis 39(6):797–802. https://doi.org/10.1086/423380
Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, Heinz WJ, Jagannatha
S, Koh LP, Kontoyiannis DP, Lee D-G, Nucci M, Pappas PG, Slavin MA, Queiroz-Telles F,
Selleslag D, Walsh TJ, Wingard JR, Maertens JA (2015) Combination antifungal therapy for
invasive aspergillosis. Ann Intern Med 162(2):81–89. https://doi.org/10.7326/M13- 2508
Mason TG, Graves SM, Wilking JN, Lin MY (2006) Effective structure factor of osmotically
deformed nanoemulsions. J Phys Chem B 110(44):22097–22102. https://doi.org/10.1021/
jp0601623
Mathavi S, Shankar R, Kavitha A, Sasikala G, Priyadharsini I (2014) A study on prevalence of pul-
monary candidiasis among tuberculosis patients and use of CHROMAGAR in identication of
CANDIDA species. J Drug Deliv Therapeut 4(3):118. https://doi.org/10.22270/jddt.v4i3.821
McCarthy DS, Pepys J (1973) Pulmonary aspergilloma-clinical immunology. Clin Exp Allergy
3(1):57–70. https://doi.org/10.1111/j.1365- 2222.1973.tb01310.x
Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E
(2004) Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care
Med 170(6):621–625. https://doi.org/10.1164/rccm.200401- 093OC
Miceli MH (2019) Central nervous system infections due to aspergillus and other hyaline molds. J
Fungi 5(3):79. https://doi.org/10.3390/jof5030079
Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, Fridkin SK,
Pappas PG, Warnock DW (2005) Incidence of invasive aspergillosis following hematopoietic
stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 43(s1):49–58. https://doi.org/10.1080/13693780400020113
Moss RB (2005) Pathophysiology and immunology of allergic bronchopulmonary aspergillosis.
Med Mycol 43(s1):203–206. https://doi.org/10.1080/13693780500052255
Mullen P, Jude C, Borkon M, Portereld J, Walsh TJ (1986) Aspergillus mural endocarditis. Chest
90(3):451–452. https://doi.org/10.1378/chest.90.3.451
Naaraayan A, Kavian R, Lederman J, Basak P, Jesmajian S (2015) Invasive pulmonary aspergillo-
sis—case report and review of literature. J Community Hosp Intern Med Perspect 5(1):26322.
https://doi.org/10.3402/jchimp.v5.26322
Nagai H, Guo J, Choi H, Kurup V (1995) Interferon- and tumor necrosis factor- protect mice from
invasive aspergillosis. J Infect Dis 172(6):1554–1560. https://doi.org/10.1093/infdis/172.6.1554
Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster
K, Marr K (2009) Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy
(PATH) Alliance Registry. Clin Infect Dis 48(3):265–273. https://doi.org/10.1086/595846
Neofytos D, Chatzis O, Nasioudis D, Boely Janke E, Doco Lecompte T, Garzoni C, Berger C,
Cussini A, Boggian K, Khanna N, Manuel O, Mueller NJ, van Delden C (2018) Epidemiology,
risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in
the Swiss transplant cohort study. Transpl Infect Dis 20(4):e12898. https://doi.org/10.1111/
tid.12898
Neoh CF, Snell GI, Kotsimbos T, Levvey B, Morrissey CO, Slavin MA, Stewart K, Kong DCM
(2011) Antifungal prophylaxis in lung transplantation—a world-wide survey. Am J Transplant
11(2):361–366. https://doi.org/10.1111/j.1600- 6143.2010.03375.x
D. Das et al.
14 Therapeutic Strategies and Challenges in the Management of Aspergillus…
Odds FC, Brown AJP, Gow NAR (2003) Antifungal agents: mechanisms of action. Trends
Microbiol 11(6):272–279. https://doi.org/10.1016/S0966- 842X(03)00117- 3
Panackal AA, Li H, Kontoyiannis DP, Mori M, Perego CA, Boeckh M, Marr KA (2010)
Geoclimatic inuences on invasive aspergillosis after hematopoietic stem cell transplantation.
Clin Infect Dis 50(12):1588–1597. https://doi.org/10.1086/652761
Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble
LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson
TF, Perl TM, Oster RA, Schuster MG etal (2010) Invasive fungal infections among organ
transplant recipients: results of the transplant-associated infection surveillance network
(TRANSNET). Clin Infect Dis 50(8):1101–1111. https://doi.org/10.1086/651262
Pasqualotto AC, Denning DW (2006) Post-operative aspergillosis. Clin Microbiol Infect
12(11):1060–1076. https://doi.org/10.1111/j.1469- 0691.2006.01512.x
Patil A, Majumdar S (2017) Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol
69(12):1635–1660. https://doi.org/10.1111/jphp.12780
Patterson R (1982) Allergic bronchopulmonary aspergillosis: staging as an aid to management.
Ann Intern Med 96(3):286. https://doi.org/10.7326/0003- 4819- 96- 3- 286
Patterson K, Strek ME (2010) Allergic bronchopulmonary aspergillosis. Proc Am Thorac Soc
7(3):237–244. https://doi.org/10.1513/pats.200908- 086AL
Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG,
Stevens DA, Graybill JR (2000) Invasive aspergillosis disease spectrum, treatment practices,
and outcomes. Medicine 79(4):250–260. https://doi.org/10.1097/00005792- 200007000- 00006
Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis
DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ,
Wingard JR, Young J-AH, Bennett JE (2016) Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect
Dis 63(4):e1–e60. https://doi.org/10.1093/cid/ciw326
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerg-
ing platform for cancer therapy. Nat Nanotechnol 2(12):751–760. https://doi.org/10.1038/
nnano.2007.387
Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A, Capanni M, Urbani E, Mancusi A,
Aversa F, Martelli MF, Romani L, Velardi A (2005) Transferring functional immune responses
to pathogens after haploidentical hematopoietic transplantation. Blood 106(13):4397–4406.
https://doi.org/10.1182/blood- 2005- 05- 1775
Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, Raghavan A,
Oldenburg CE, Ray KJ, Zegans ME, McLeod SD, Porco TC, Acharya NR, Lietman TM,
Mycotic Ulcer Treatment Trial Group (2013) The mycotic ulcer treatment trial. JAMA
Ophthalmol 131(4):422. https://doi.org/10.1001/jamaophthalmol.2013.1497
Punia S, Dhull SB, Kunner P, Rohilla S (2020) Effect of γ-radiation on physico-chemical, mor-
phological and thermal characteristics of lotus seed (Nelumbo nucifera) starch. Int J Biol
Macromol 157:584–590. https://doi.org/10.1016/j.ijbiomac.2020.04.181
Quirós J, Gonzalo S, Jalvo B, Boltes K, Perdigón-Melón JA, Rosal R (2016) Electrospun cellulose
acetate composites containing supported metal nanoparticles for antifungal membranes. Sci
Total Environ 563–564:912–920. https://doi.org/10.1016/j.scitotenv.2015.10.072
Reija MF (2002) Invasive maxillary aspergillosis: report of a case and review of the literature.
Med Oral 7:200
Rocha EMF, Garcia-Effron G, Park S, Perlin DS (2007) A Ser678Pro substitution in Fks1p con-
fers resistance to Echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother
51(11):4174–4176. https://doi.org/10.1128/AAC.00917- 07
Rogers TR, Verweij PE, Castanheira M, Dannaoui E, White PL, Arendrup MC, Arendrup MC,
Arikan-Akdagli S, Barchiesi F, Buil J, Castanheira M, Chryssanthou E, Friberg N, Guinea J,
Hamal P, Hilmarsdottir I, Klimko N, Kurzai O, Lagrou K etal (2022) Molecular mechanisms
of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for
their laboratory detection and clinical implications. J Antimicrob Chemother 77(8):2053–2073.
https://doi.org/10.1093/jac/dkac161
361
362
Romani L, Puccetti P, Bistoni F (1997) Interleukin-12in infectious diseases. Clin Microbiol Rev
10(4):611–636. https://doi.org/10.1128/CMR.10.4.611
Rosenvold LK (1942) Dacryocystitis and blepharitis due to infection by Aspergillus niger*. Am J
Ophthalmol 25(5):588–589. https://doi.org/10.1016/S0002- 9394(42)91587- 3
Routray C, Nwaigwe C (2020) Sternal osteomyelitis secondary to aspergillus fumigatus after cardio-
thoracic surgery. Med Mycol Case Rep 28:16–19. https://doi.org/10.1016/j.mmcr.2020.03.003
Ruhnke M, Böhme A, Buchheidt D, Donhuijsen K, Einsele H, Enzensberger R, Glasmacher A,
Gümbel H, Heussel C-P, Karthaus M, Lambrecht E, Südhoff T, Szelényi H (2003) Diagnosis
of invasive fungal infections in hematology and oncology. Ann Hematol 82(0):S141–S148.
https://doi.org/10.1007/s00277- 003- 0768- 0
Sabino R, Veríssimo C, Viegas C, Viegas S, Brandão J, Alves-Correia M, Borrego L-M, Clemons
KV, Stevens DA, Richardson M (2019) The role of occupational Aspergillus exposure in the
development of diseases. Med Mycol 57(Supplement_2):S196–S205. https://doi.org/10.1093/
mmy/myy090
Samson RA, Houbraken J, Thrane U, Frisvad JC, Andersen B (2010) Food and indoor fungi, 2nd
edn. CBS-KNAW Fungal Biodiversity Centre, Utrecht
Santos L, Nerves N, Xerinda S, Sarmento A (2014) Endotracheal tuberculosis and aspergillosis
co-infection manifested as acute respiratory failure: a case report. Mycobact Dis 4(4):1000160.
https://doi.org/10.4172/2161- 1068.1000160
Sarwar M, Gardezi S, Zaman G, Ikram A, Satti L, Khadim M (2020) Evaluation of galactoman-
nan and beta-d-glucan assays for the diagnosis of invasive aspergillosis in clinically suspected
cases. J Pak Med Assoc 70:442. https://doi.org/10.5455/JPMA.1476
Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, Thiel E (2007) Poor efcacy of ampho-
tericin B-based therapy in CNS aspergillosis. Mycoses 50(3):196–200. https://doi.
org/10.1111/j.1439- 0507.2007.01345.x
Scorzoni L, de Paula e Silva ACA, Marcos CM, Assato PA, de Melo WCMA, de Oliveira HC,
Costa-Orlandi CB, Mendes-Giannini MJS, Fusco-Almeida AM (2017) Antifungal therapy:
new advances in the understanding and treatment of mycosis. Front Microbiol 8:36. https://doi.
org/10.3389/fmicb.2017.00036
Segal BH, Romani LR (2009) Invasive aspergillosis in chronic granulomatous disease. Med Mycol
47(s1):S282–S290. https://doi.org/10.1080/13693780902736620
Seif M, Kakoschke TK, Ebel F, Bellet MM, Trinks N, Renga G, Pariano M, Romani L, Tappe B,
Espie D, Donnadieu E, Hünniger K, Häder A, Sauer M, Damotte D, Alifano M, White PL, Backx
M, Nerreter T etal (2022) CAR T cells targeting aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models. Sci Transl Med 14(664):eabh1209.
https://doi.org/10.1126/scitranslmed.abh1209
Shao C, Qu J, He L, Zhang Y, Wang J, Zhou H, Wang Y, Liu X (2005) Dendritic cells transduced
with an adenovirus vector encoding interleukin-12 are a potent vaccine for invasive pulmonary
aspergillosis. Genes Immun 6(2):103–114. https://doi.org/10.1038/sj.gene.6364167
Sharma D, Mahajan N, Rao S, Khurana N, Jain S (2012) Invasive maxillary aspergillosis mas-
querading as malignancy in two cases: utility of cytology as a rapid diagnostic tool. J Cytol
29(3):194. https://doi.org/10.4103/0970- 9371.101171
Singh NM, Husain S (2013) Aspergillosis in solid organ transplantation. Am J Transplant
13:228–241. https://doi.org/10.1111/ajt.12115
Singh N, Paterson DL (2005) Aspergillus infections in transplant recipients. Clin Microbiol Rev
18(1):44–69. https://doi.org/10.1128/CMR.18.1.44- 69.2005
Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, Chourasia MK (2017) Nanoemulsion:
concepts, development and applications in drug delivery. J Control Release 252:28–49. https://
doi.org/10.1016/j.jconrel.2017.03.008
Soman SO, Vijayaraghavan G, Padmaja NP, Warrier AR, Unni M (2014) Aspergilloma of the heart.
Indian Heart J 66(2):238–240. https://doi.org/10.1016/j.ihj.2013.12.006
Song JC, Stevens DA (2016) Caspofungin: pharmacodynamics, pharmacokinetics, clinical
uses and treatment outcomes. Crit Rev Microbiol 42(5):813–846. https://doi.org/10.310
9/1040841X.2015.1068271
D. Das et al.